Bain Capital Reduces Stake in Cholesterol Drug Developer Below 5%

NewAmsterdam Pharma Co. N.V. (NAMS) disclosed that Bain Capital Life Sciences–affiliated funds sold shares under Rule 144 on May 8, 11 and 12, reducing their stake to below 5%.

The funds’ combined holdings, including common shares and warrants, fell to approximately 3.3%, and they reported the change as a passive investment, with no intent to engage in management or alter company strategy.

Recently, Piper Sandler reiterated an overweight rating on the company and set a $60 target price (about KRW 80,000), while several brokerages have upwardly revised their earnings forecasts to reflect updated sales projections for obicetrapib. ()

The company is also approaching the interim analysis of its PREVAIL Phase 3 cardiovascular outcomes trial, slated for Q4 2026, making the timing of clinical data releases a key catalyst for the stock. ()

Headquartered in the Netherlands, the late-stage clinical biotech is developing obicetrapib, an oral CETP inhibitor for high-risk cardiovascular patients, and is conducting multiple global Phase 3 clinical programs. ()